Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Prim SA

Prim SA

Actions
  • Price (EUR)10.35
  • Today's Change-0.10 / -0.96%
  • Shares traded8.12k
  • 1 Year change-4.17%
  • Beta0.4828
Data delayed at least 15 minutes, as of Sep 27 2024 16:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Prim SA is a Spain-based company principally engaged in the provision of hospital supplies. The Company’s products portfolio comprises implantable orthopedic products, silicone foot products, abduction splints, mastectomy lingerie, prosthetic components, as well as articulated electric beds and various types of accessories for geriatric centers. Through its subsidiary Inmobiliaria Catharsis SA, the Company is also active in the Real State sector. Prim SA is a parent of Grupo Prim, a group which comprises such a number of controlled entities as Enraf Nonius Iberica SA, Establecimientos Ortopedicos Prim SA, and Luga Suministros Medicos SL, among others.

  • Revenue in EUR (TTM)227.46m
  • Net income in EUR11.43m
  • Incorporated--
  • Employees901.00
  • Location
    Prim SACalle Fnumero 15., Polig. Industrial numero 1MOSTOLES 28938SpainESP
  • Phone+34 913342400
  • Fax+34 913342494
  • Websitehttps://www.prim.es/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ADDvise Group AB (publ)137.06m12.20m124.98m637.0017.523.075.900.91190.71910.71918.074.100.51427.245.042,474,039.004.583.725.634.7744.8248.958.915.891.363.240.69130.940544.3038.6227.62--30.35--
EasyMotionSkin Tec GmbH-100.00bn-100.00bn130.38m17.00------------------------------------------------229.95---214.79------
Pulsion Medical Systems SE31.67m5.41m130.97m71.0024.434.7619.254.140.65490.65493.843.360.97111.773.88446,048.4016.5819.8221.2429.7263.6650.4217.0721.571.7715.740.00--20.697.87-399.21----0.00
Genovis AB11.28m1.53m131.28m37.00106.848.8850.8711.640.26350.26351.943.170.4938----3,432,973.006.7118.567.2121.4564.4165.5113.5823.88--697.000.27180.0054.5435.56449.56--47.59--
Nordhealth As41.31m-9.33m133.06m355.00--3.0091.343.22-1.40-1.406.1911.610.4329--6.731,226,052.00-9.78---11.11--85.82---22.59------0.00--18.60--21.96------
Amplitude Surgical SA104.05m43.23m145.63m416.003.531.612.661.400.90020.90022.171.970.39550.56528.83244,244.1016.21-0.365819.44-0.426779.4178.3040.98-1.081.210.41630.5395--14.44-0.0271993.58--7.11--
EKF Diagnostics Holdings PLC61.04m5.72m146.22m309.0028.041.9512.212.400.01050.01050.11230.15160.63073.016.99160,728.706.345.207.356.1348.0550.0410.057.913.081,703.500.0175113.68-21.054.34123.28-25.3030.37--
Onward Medical NV0.00-35.15m163.70m99.00--8.42-----1.09-1.090.000.60790.00----0.00-66.40-55.70-79.20-61.60-------79,513.95----0.4855---34.62---10.40--32.59--
Agfa Gevaert NV1.13bn-32.00m163.87m5.03k--0.456740.970.1451-0.2057-0.27187.292.450.80562.224.44224,631.90-2.21-4.24-3.10-6.2231.5329.49-2.75-5.601.243.130.306--0.4367-12.1071.20---3.20--
Bactiguard Holding AB20.46m-6.75m169.29m177.00--6.08--8.27-2.17-2.176.589.370.32663.617.521,062,240.00-10.77-7.56-14.93-8.8143.8047.91-32.99-26.280.5741-3.930.4215---11.966.46-161.71--8.43--
Stille AB38.15m4.25m175.45m143.0031.232.9228.734.606.856.8561.3473.400.62191.978.164,053,557.006.937.038.328.1947.9743.9311.149.851.0711.550.0021.9819.7016.78-2.485.3423.62--
Prim SA227.46m11.43m181.50m901.0015.481.398.130.7980.67170.671713.377.461.141.964.39252,736.005.736.688.348.9038.2838.115.026.431.13--0.13159.389.7710.0051.02-2.1412.86-5.01
Sedana Medical AB (publ)14.98m-3.68m201.39m81.00--2.43--13.45-0.4175-0.41751.709.790.16091.1910.822,135,139.00-3.95-5.77-4.17-6.0870.3264.06-24.59-36.135.66--0.0081--25.2321.5918.90--42.12--
Lumibird SA203.56m7.13m215.09m1.05k23.880.9868.791.060.35590.35599.148.620.52381.094.05193,497.101.833.132.443.9961.6861.763.505.891.622.470.42870.006.6015.12-37.23-2.4718.34--
Tristel Plc47.31m7.23m234.92m213.0031.526.0322.924.970.12560.12560.82190.65670.9921.516.26185,394.4015.178.8617.1010.2482.5980.6315.2910.633.93411.730.1605109.9915.7010.14351.986.409.8818.05
Data as of Sep 27 2024. Currency figures normalised to Prim SA's reporting currency: Euro EUR

Institutional shareholders

14.07%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 27 Apr 20231.70m9.99%
Independance AM SICAVas of 31 Dec 2023223.67k1.31%
KBC Asset Management NVas of 31 Dec 2023157.28k0.92%
Magallanes Value Investors SA SGIICas of 30 Jun 2024103.07k0.61%
Santander Private Banking Gestion SA SGIICas of 30 Jun 202469.88k0.41%
Dimensional Fund Advisors LPas of 04 Jul 202456.54k0.33%
March Asset Management SGIIC SAUas of 31 Dec 202324.87k0.15%
GVC Gaesco Gesti�n SGIIC SAas of 30 Jun 202421.81k0.13%
HOROS Asset Management SGIIC SAas of 30 Jun 202419.78k0.12%
Kontor St�wer Asset Management GmbHas of 28 Jun 202417.50k0.10%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.